Friday, May 19, 2017 10:28:05 AM
Tetra Bio-Pharma Inc. (CSE: C.TBP, OTCQB: GRPOF, Forum) said Thursday it has submitted a provisional patent application with the U.S. patent and trademark office for a pharmaceutical drug formulation to treat various forms of cancer and ocular disease.
The global market for cancer drugs has hit US$100 billion in annual sales, and could reach US$147 billion by 2018, according to a new report by IMS Institute for Healthcare Informatics.
The Ontario-based company was in the news recently when it and and Aphria Inc. (TSX: V.APH, OTCQB: APHQF, Forum) announced plans for the joint distribution of dried medical cannabis in the maritime provinces and Quebec.
Tetra and Aphria will enter into a joint supply agreement, the companies said in a press release.
Read more at http://www.stockhouse.com/news/newswire/2017/05/18/tetra-bio-pharma-files-patent-for-treatment-cancer-ocular-disease#v5bq4J20Y5Hzv1ck.99
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM
ECGI Holdings Accelerates Strategic Initiatives by Securing First of Two $125,000 Convertible Notes • ECGI • Jun 4, 2024 12:15 PM